Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Krka Welcomes ‘Highest Ever Net Profit’ As EBITDA Jumps By 30%

Slovenian Company Publishes Preliminary 2020 Financial Results

Executive Summary

Slovenia’s Krka saw business boom as it rushed to supply the demand created by the coronavirus pandemic, while reaping the benefits from its vertically integrated business model. CEO and president of the management board Jože Colarič has just been appointed for another six-year term.

You may also be interested in...



Krka Focuses On Extending Cardiovascular And Oncology Range

After reporting a profitable 2020, Slovenia’s Krka is looking to expand its cardiovascular and oncology portfolio, while adding to its diabetes and central nervous system range as well. The firm has also started manufacturing in China for the local market.

Krka, Accord And Xeris Pick Up European Nods

The EMA’s CHMP has recommended granting pan-European marketing authorizations for Krka’s lenalidomide versions of Revlimid and Accord’s sunitinib rival to Sutent, as well as Xeris Pharmaceuticals’ glucagon hybrid rival to Glucagen.

EBITDA Margin Of 33% Not Sustainable, Krka Underlines

Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel